<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197726</url>
  </required_header>
  <id_info>
    <org_study_id>QIB02/2019</org_study_id>
    <nct_id>NCT04197726</nct_id>
  </id_info>
  <brief_title>Glycaemic Response to High REsistant STarch Bread</brief_title>
  <acronym>REST</acronym>
  <official_title>Glycaemic Response to High REsistant STarch Bread</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quadram Institute Bioscience</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Quadram Institute Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates if the consumption of one sbeIIa/b white bread with high resistant
      starch content will result in a lower blood glucose response and increased satiety compared
      with reference white bread. All participants will be asked to consume once the sbeIIa/b white
      bread and the reference white bread during different visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an attempt to increase dietary fibre intake, research has focused on developing
      wheat-based food products with novel fibres and starches to complement fibre intake from
      whole grain foods. Resistant starch is starch that escapes digestion in the small intestine
      and may be fermented in the large intestine by the microbiota. Resistant starch is a type of
      dietary fibre and it is normally found in wheat-based foods made from refined flour but only
      in small amounts. White bread made from sbeIIa/b wheat, which has high levels of resistant
      starch (a type of fibre), is showing promise in modulating blood glucose response and
      increasing satiety compared with conventional white bread.

      The primary aim of this study is to determine whether consumption of sbeIIa/b white bread at
      breakfast, gives rise to a lower postprandial blood glucose response compared with
      consumption of a reference white bread in healthy individuals.

      Additional aims of the study include: determining whether consumption of sbeIIa/b white bread
      by healthy subjects, gives rise to a lower glucose concentration in interstitial fluid, as
      measured by a Continuous Glucose Monitoring system (CGM), compared with consumption of
      control white bread; and exploring satiety and energy intake changes in healthy individuals
      following consumption of sbeIIa/b white bread at breakfast, compared with consumption of
      control white bread.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind randomised crossover study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial capillary glucose concentration</measure>
    <time_frame>3.5 hours</time_frame>
    <description>Glucose concentration in capillary blood measured by finger prick test after the consumption of sbeIIa/b white bread compared to control white bread.
Measurements will be taken during intervention visit 1 and 2 at -15, -10, -5, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose concentration in interstitial fluid</measure>
    <time_frame>4 hours</time_frame>
    <description>Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of sbeIIa/b white bread compared to control white bread.
Measurements will be taken during intervention visit 1 and 2 between -30 to 210 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ad libitum intake</measure>
    <time_frame>2 hours</time_frame>
    <description>Mean energy intake (kcal) at lunch after consumption of sbeIIa/b and control white bread.
Measurements will be taken once during intervention visit 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose concentration in interstitial fluid</measure>
    <time_frame>4 hours</time_frame>
    <description>Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of ad libitum lunch to explore any second meal effects caused by prior intake of either sbeIIa/b white bread and control white bread at breakfast.
Measurements will be taken during intervention visit 1 and 2 between 225 to 465 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>3 hours</time_frame>
    <description>Change of hunger feeling (appetite) will be examined using visual analog scale (0-10), 0 least and 10 greatest.
Measurements will be taken during intervention visit 1 and 2, at 0, 32, 92, 182 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory questionnaire</measure>
    <time_frame>30 minutes</time_frame>
    <description>Sensory perception of sbeIIa/b white bread and control white bread will be evaluated using a nine-point hedonic scale to determine any differences overall acceptability based on specific attributes.
A Just-About-Right (JAR) scale with five anchor points will be used to measure the appropriateness of the level of specific attributes to evaluate aroma, appearance, taste and texture of breads.
Measurements will be taken once during intervention visit 1 and 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Blood Glucose Response</condition>
  <arm_group>
    <arm_group_label>sbeIIa/b white bread</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sbeIIa/b white bread with high resistant starch content</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control white bread</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference white bread (wild-type)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sbeIIa/b white bread</intervention_name>
    <description>one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast</description>
    <arm_group_label>Control white bread</arm_group_label>
    <arm_group_label>sbeIIa/b white bread</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control white bread</intervention_name>
    <description>one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast</description>
    <arm_group_label>Control white bread</arm_group_label>
    <arm_group_label>sbeIIa/b white bread</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  Aged 18 to 65 years

          -  BMI between 18-25 kg/m2

          -  Non-smokers

          -  Those that live within a 40-mile radius of Norwich

        Exclusion Criteria:

          -  Fasting glucose &gt;6.1 mmol/L and/or HbA1c&gt;42 mmol/mol, as assessed by a fasting blood
             test

          -  Eligibility screening results indicate they are not suitable to take part in this
             study

          -  Smokers (if they have smoked within the 6 weeks prior to the study or during the
             study)

          -  Suffer from allergy, intolerance, or sensitivity to gluten, yeast or any of the food
             ingredients used in this study

          -  Have a known allergy to adhesives that would prevent proper attachment of the
             Continuous Glucose Monitoring sensors

          -  Are pregnant and/or have been pregnant in the last year or are lactating and/or
             breastfeeding

          -  Are currently suffering from, or have ever suffered from eating disorders, any
             diagnosed gastrointestinal disease, gastrointestinal disorders including regular
             diarrhoea and constipation (excluding hiatus hernia unless symptomatic) or other
             inflammatory diseases like rheumatoid arthritis (RA), polymyalgia rheumatica or other
             connective tissues diseases

          -  Have undergone gastrointestinal surgery; this will be assessed on an individual basis

          -  Have been diagnosed with diabetes, anaemia as this may affect the study outcome

          -  Have been diagnosed with any long-term medical condition that may affect the study
             outcome (e.g. cardiovascular diseases, cancer)

          -  Regularly take over-the-counter medications for digestive/gastrointestinal conditions

          -  Use medications likely to interfere with energy metabolism, appetite regulation and
             hormonal balance, including long-term steroids, antibiotics. They may be able to
             participate if 4 weeks or more have passed from the end of a course such medication

          -  Regularly take laxatives (once a month or more) as this may affect blood glucose
             levels

          -  Take certain dietary supplements or herbal remedies and are unwilling to stop taking
             them (if required) for two weeks prior to and during the study period

          -  Are on, or plan to start, a diet programme that may affect the study outcome (e.g. 5:2
             fasting diet) unless willing to abstain for 1 month prior to and during the study
             period

          -  Went through a weight change of â‰¥ 3kg in the preceding 2 months

          -  Have a recent history of substance abuse

          -  Regularly consume more than 14 units of alcohol a week

          -  Are unwilling to suspend smoking and vaping for the duration of the study.

          -  Are participating in another research project that involves dietary intervention or
             blood sampling.

          -  Are unwilling to provide GPs contact details

          -  Are related to or living with any member of the study team.

          -  Are unable to provide written informed consent

          -  Have not donated blood or taken part in another dietary intervention in the last 16
             weeks and are unwilling to wait until 16 weeks have elapsed

          -  Those with abnormal blood pressure measurements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Corrado, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhD student</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quadram Institute</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycaemic response</keyword>
  <keyword>Resistant starch</keyword>
  <keyword>Bread</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available after publication in scientific journal within 18 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access will be reviewed by the study team</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

